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Abstract The interaction between a chemical and a cell
may strongly depend on whether this cell is normal or
pathological. Side effects of anticancer drugs may some-
times overcome their beneﬁt action, so it is important to
investigate their effect in both the target and normal cells.
Capecitabine (Xeloda, CAP), a prodrug of 5-ﬂuorouracil, is
mainly used in colon cancer, but little is known about its
action in head and neck cancer. We compared the cyto- and
genotoxicity of CAP in head and neck HTB-43 cells and
normal human lymphocytes by comet assay and ﬂow
cytometry. CAP at concentration up to 50 lM signiﬁcantly
decreased the viability of the cancer cells, whereas it did
not affect normal lymphocytes. The drug did not interact
with isolated plasmid DNA, but it damaged DNA in both
cancer and normal cells. However, the extent of the dam-
age in the former was much higher than in the latter. CAP
induced apoptosis in the cancer cells, but not in normal
lymphocytes. Pre-treatment of the cells with the nitrone
spin traps a-(4-pyridil-1-oxide)-N-tert-butylnitrone and
N-tert-butyl-a-phenylnitrone decreased the extent of CAP
induced DNA damage, suggesting that free radicals may be
involved in the formation of DNA lesions induced by CAP.
The drug evoked an increase in the G0/G1 cell population
accompanied by a decrease in the S cell population. CAP
may evoke a pronounced cyto- and genotoxic effects in
head and neck cancer cells, whereas it may or may not
induce such effects in normal cells to far lesser extent.
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Introduction
Chemotherapy in head and neck cancer is a multi-stages
process, in which 5-ﬂuorouracil (5-FU), a ﬂuorinated ana-
log of uracil, plays a pivotal role [1, 2]. This drug displays
activity in various regimes of therapy of squamous cell
carcinoma of the head and neck (HNSCC) and its combi-
nation with cisplatin and radiation improves the efﬁcacy of
the treatment. After entering the cell, 5-FU is metabolized
in a rather complex way, including at least four pathways,
one of which gives rise to 5-FUTP [3]. Because the atom of
ﬂuorine is similar in size to hydrogen in UTP, RNA poly-
merases include 5-FU in all classes of RNA. 5-FU may also
produce 5-FdUMP, which is an inhibitor of thymidylate
synthase (TS), involved in the synthesis of DNA. TS
inhibiting results in blocking of formation of dTMP and,
therefore, decreasing the availability of dTTP for DNA
replication and repair. Cytotoxic effect of 5-FU can also be
mediated by its incorporation into DNA and changes in
some membrane function in cancer cells treated with the
drug [4]. The use of 5-FU has several limitations. The
activity of the drug is limited by its rapid degradation by
the cytosolic enzyme dihydropyrimidine dehydrogenase,
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this enzyme displays a considerable variation between tis-
sues within one subject and among different subjects, the
bioavailability of 5-FU can be unpredictable [5]. Although
5-FU proved to be effective in many chemotherapy regimes
in several cancer types, it is not free from adverse side
effects, including fever, febrile neutropenia, anorexia,
nausea, vomiting, diarrhea, stomatitis, alopecia, fatigue,
hand-foot syndrome [6].
To overcome some limitations in therapy with 5-FU, its
oral prodrugs have been synthesized. Doxiﬂuridine
(50-deoxy-5-ﬂuoridine, 50-DFUR) is a prodrug of 5-FU and
its carbamate derivative is capecitabine (Xeloda, N4-pen-
tyloxycarbonyl-50-deoxy-5-ﬂuorocytidine, CAP, Fig. 1)t h a t
is absorbed through intestine in the prodrug form and it is
metabolized to 5-FU in three activation stages. The ﬁnal
stage require thymidine phosphorylase, an enzyme present
in tumor cells in much higher concentration than in normal
cells, which results in almost threefold higher concentra-
tion of 5-FU in malignant compared with non-malignant
tissues [7]. CAP was used with success in the treatment of
colorectal cancers [8]. Recently, an anti-angiogenic
potential of CAP in human colorectal cancer xenograft was
reported [9].
Because major chemotherapeutic treatment in head and
neck cancer is based on 5-FU and CAP may improve the
anticancer action of 5-FU, it was rational to consider it in
head and neck cancer therapy [10]. The drug has been used
in HNSCC chemotherapy singly or in a combination with
other drugs: cisplatin, oxaliplatin, vorinostat, a histone
deacetylaseinhibitor,docetaxel,paclitaxelandseveralother
agents [11–16]. It was successfully applied in the therapy of
nasopharyngealcancerasasingleagentanditsmonotherapy
is postulated to be considered in patients with recurrent/
metastatic disease [17].
The results of several studies indicate that CAP can
induce several side effects, among them hematological
syndromes—neutropenia, anemia and thrombocytopenia
seem to be most serious [18]. Besides hematological
disturbances several other effects, including diarrhea,
hand-foot syndrome, hypotension, abdominal pain, and
asthenia have been reported [19]. Therefore, in the light of
the research performed so far, blood toxicity seems to be a
major side effect of CAP. Several other effects not-related
to blood may also be associated with anticancer therapy
with CAP. However, little is know about the interaction of
the drug with DNA of normal cells, but this issue should be
addressed, because genotoxic effect of an anticancer drug
in normal cells may lead to genomic instability, mutations
and induction of secondary malignances, which can be
considered as a major side effect of chemotherapy.
In the present work we investigated cyto- and genotoxic
action of CAP in HNSCC HTB-43 cells and human lym-
phocytes obtained from healthy individuals. We measured
cell viability, DNA damage and repair, cell cycle and
apoptosis in these cells exposed to CAP.
Materials and methods
Chemicals
Capecitabine was a gift of Roche Pharmaceuticals (Basel,
Switzerland). QIAamp DNA Blood Mini Kit for isolation
of high-molecular-weight DNA was obtained from QIA-
GEN (Chatsworth, CA, USA). Plasmid DNA puriﬁcation
kit was provided by EURx (Gdansk, Poland). Cell viability,
apoptosis and cell cycle kits were purchased in BD Bio-
sciences (San Jose, CA, USA). Gradisol, low melting point
(LMP) and normal melting point (NMP) agarose, phos-
phate buffered saline (PBS), 40, 6-diamidino-2-pheny-
lindole (DAPI), dimethyl sulfoxide (DMSO), fetal bovine
serum (FBS), MTT, lectin, penicillin, streptomycin,
a-(4-pyridil-1-oxide)-N-tert-butylnitrone (POBN), N-tert-
butyl-a-phenylnitrone (PBN), Bradford reagent were pur-
chased from Sigma (St. Louis, MO, USA). ApoAlert
Caspase Colorimetric Assay Kit was bought from Clontech
Laboratories Inc (Palo Alto, CA, USA). All other chemi-
cals were of the highest commercial grade available.
Cells
Human lymphocytes were isolated from peripheral blood
obtained from healthy, sex- and age matched donors by
centrifugation in a density gradient of Gradisol L (15 min,
2809g,4 C). The cell viability was measured by trypan
blue exclusion staining and was found to be about 99%.
Human larynx cancer cell line HTB-43 was purchased
from the ATCC (Rockville, MD, USA). The cells were
grown in EMEM medium with 10% FBS, 100 IU/ml
penicillin and 100 g/ml streptomycin in a 5% CO2 atmo-
sphere at 37C for 3–4 days. Just before use, they were Fig. 1 Structure of 5-ﬂuorouracil (5-FU) and CAP
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123trypsinized and re-suspended in EMEM to a ﬁnal concen-
tration of 1–2 9 10
5 cells/ml.
Escherichia coli cells, strain DH5a cells with pUC19
plasmid, were grown in a LB broth at 37C overnight.
Cell treatment
CPA at ﬁnal concentrations from 0.5 to 500 lM was added
to the cells in EMEM from its 50 mM ethanolic solution.
The ﬁnal concentration of ethanol in the samples did not
exceed 0.3%, which did not inﬂuence processes under
study (results not shown). The control cells received only
the growth medium. To examine DNA damage and cell
viability, the cells were incubated with the drug for 1 h at
37C. Each experiment included a positive control, which
was hydrogen peroxide at 20 lM for 15 min on ice. H2O2
produced pronounced DNA damage, which resulted in tail
DNA of 30–40%.
Cell viability
The BD Cell Viability Kit was used. The kit contains thi-
azole orange (TO) solution to stain all cells and propidium
iodide (PI) to stain dead cells. Aliquots of 2.0 ll of TO and
1.0 ll of PI were added to 1 ml of cell suspension con-
taining 5 9 10
5 cells, producing the ﬁnal staining con-
centrations of 84 nM and 4.3 lM, respectively. The
mixture was gently shaken and incubated for 5 min in
room temperature to allow both dyes to enter the cells. The
samples were acquired on a LSRII (Becton Dickinson, San
Jose, USA) ﬂow cytometer equipped with 488 nm laser
excitation and BD FACSDiva software v 4.1.2. 5 9 10
4
cells were analyzed in each experiment and each experi-
ment was repeated in triplicate. In this and all next
experiments the samples were coded prior to measure-
ments, so the investigator did not know the exposure mode
for any particular sample.
Plasmid relaxation assay
pUC19 plasmids were isolated from DH5a Escherichia coli
cells with Genematrix Plasmid Miniprep DNA Puriﬁcation
Kit (EURx, Gdansk, Poland) according to the manufacturer
instruction. Plasmids were exposed to UV irradiation at
35 J/m
2 (positive control) to check the migration of its
multimeric forms (supercoiled, nicked circular and linear).
UV irradiation induced strand breaks of DNA and caused
the relaxation of supercoiled plasmid—one break is enough
to relax one molecule of the plasmid. Structural differences
between supercoiled, nicked circular and linear forms of
the plasmid accounted for their different electrophoretic
mobility. Plasmid samples at 250 ng/ll were subjected to
1% agarose gel electrophoresis carried out in Tris–Borate–
EDTA (TBE) buffer. The gel was stained with ethidium
bromide (0.5 mg/ml) and the plasmid DNA was visualized
under ultraviolet light (302 nm), scanned by a CCD camera
and densitometry analysis was performed with the Gene-
Tools by Syngene (Cambridge, UK) software. UV irradi-
ation was performed at 4C with UVC-6-12 lamp (NeoLab,
Heidelberg, Germany) emitting UV light at 254 nm at dose
rate of 0.12 J m
-2 s
-1. The ability of CAP to damage
DNA was quantiﬁed by calculating the ratio of open cir-
cular DNA to the total amount of DNA (R). The values for
supercoiled DNA were multiplied by 1.66 to correct for the
decreased intercalating ability of ethidium bromide [20].
Comet assay
The comet assay was performed under alkaline conditions
essentially according to the procedure of Singh et al. with
modiﬁcations as described previously [21–23]. A freshly
prepared suspension of cells in 0.75% LMP agarose dis-
solved in PBS was spread onto microscope slides precoated
with 0.5% NMP agarose. The cells were then lysed for 1 h
at 4C in a buffer consisting of 2.5 M NaCl, 100 mM
EDTA, 1% Triton X-100, 10 mM Tris, pH 10. After lysis,
the slides were placed in an electrophoresis units, the DNA
was allowed to unwind for 40 min in the electrophoretic
solution consisting of 300 mM NaOH, 1 mM EDTA,
pH[13. Electrophoresis was conducted at 4C (the tem-
perature of the running buffer did not exceeded 12C) for
20 min at an electric ﬁeld strength of 0.73 V/cm (29 mA).
The slides were then neutralized with 0.4 M Tris, pH 7.5,
stained with 2 lg/ml of DAPI and covered with cover slips.
To prevent additional DNA damage, all the steps described
above were conducted under dimmed light or in the dark.
In the neutral version of the comet assay, electrophoresis
was run in a buffer consisting of 100 mM Tris and 300 mM
sodium acetate at pH adjusted to 9.0 by glacial acetic acid
[24]. Electrophoresis was conducted for 60 min, after a
20 min equilibrium period, at an electric ﬁeld strength of
0.41 V/cm (50 mA) at 4C.
The slides were examined at 2009 magniﬁcation in an
Eclipse ﬂuorescence microscope (Nikon, Tokyo, Japan)
attached to a COHU 4910 video camera (Cohu, Inc., San
Diego, CA) equipped with a UV ﬁlter block consisting an
excitation ﬁlter (359 nm) and barrier ﬁlter (461 nm) and
connected to a personal computer-based image analysis
system, Lucia-Comet v. 4.51 (Laboratory Imaging, Praha,
Czech Republic). Fifty images were randomly selected
from each sample and the comet tail DNA was measured.
Two parallel tests with aliquots of the same sample of cells
were performed for a total of 100 cells. Each experiment
was repeated three times. Percentage of DNA in the tail
(% tail DNA) was analyzed. It is positively correlated with
the level of DNA breakage or/and alkali labile sites in the
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123cell and is negatively correlated with the level of DNA
crosslinks [25]. For neutral version, this quantity correlates
positively with DNA double strand breaks. The mean value
of the % tail DNA in a particular sample was taken as an
index of DNA damage in this sample.
DNA repair enzyme treatment
To assess the role of oxidative modiﬁcations to the DNA
bases in the genotoxicity of CAP, we employed two DNA
repair enzymes, endonuclease III (Endo III) and formam-
idopyrimidine-DNA glycosylase (Fpg). After incubation
with CAP and cell lysis the slides from the comet assay
were washed 39 in the enzyme buffer containing 40 mM
HEPES–KOH, 0.1 M KCl, 0.5 mM EDTA, 0.2 mg/ml
bovine serum albumin, pH 8.0 and drained. The agarose on
slides was covered with 30 ll of the enzyme buffer either
with or without enzyme at 1 lg/ml, sealed with a cover
glass and incubated for 30 min at 37C[ 24]. The slides
were processed as described in ‘‘Comet assay’’. To check
the ability of both enzymes to recognize the DNA oxidative
damage, we exposed the lymphocytes to 10 lM hydrogen
peroxide for 10 min on ice (positive control). Since enzy-
matic buffer induced DNA damage the values of the %
DNA in tail in the buffer only were subtracted from the
value for the enzyme with buffer.
Spin trap treatment
In spin trapping experiments, the incubation with CAP was
carried out in the presence of POBN or PBN at a ﬁnal
concentration of 100 lM. Each spin trap was added to the
cells 15 min prior to the CAP incubation. The cells were
then processed as described previously. Each experiment
included a positive control, which was hydrogen peroxide
at 10 lM applied for 10 min on ice.
Apoptosis
The BD Annexin V-FITC Apoptosis Detection Kit I was
used to measure apoptosis. The kit contains Annexin V
conjugated to the ﬂuorochrome FITC that has afﬁnity to the
phosphatidylserine, which is transferred through cell
membrane in the earlier stages of apoptosis. PI was used to
distinguish early apoptotic cells from cells undergo late
apoptosis or necrosis. Cells that are viable are Annexin
V-FITC and PI negative, cells that are in early apoptosis
are Annexin-FITC positive and PI negative, cells that are in
late apoptosis are both Annexin-FITC and PI positive, cells
already dead are only PI positive. After 6 h of incubation
with UDMA cells were washed in cold PBS and resus-
pended in 19 binding buffer at 10
6 cells/ml. Five micro-
liter of Annexin V-FITC and 5 ll of PI were added to an
aliquot of 100 ll (10
5 cells) of cells suspension, gently
mixed by pipetting and incubated for 30 min at room
temperature in the dark. Next, 400 llo f1 9 binding buffer
was added to each tube and samples were analyzed by ﬂow
cytometry. Each experiment had a negative, positive and
unstained control samples. About 10,000 events were
counted per sample. The apoptosis ratio was calculated as a
percent of apoptotic cells in a sample.
Cell cycle
In the cell cycle experiment, we replaced lymphocytes with
highly proliferating human cancer cells. The Cycle TEST
PLUS DNA Reagent Kit was used to determine the DNA
index (DI) and cell cycle phase distributions. Nuclei were
isolated, stained with PI and afterward analyzed on the
LSRII ﬂow cytometer according to the manufacturer
instruction. The DI was calculated by dividing the mean of
the relative content of the exposed G0/G1 population by
the mean of the control G0/G1 population. Results were
analyzed by Flow Jo software (v. 7.2.4).
DNA repair
To examine DNA repair, the cells after a 1 h pre-treatment
with 10 or 50 lM CAP at 37C were washed and re-sus-
pended in a fresh, CAP-free RPMI 1640 medium preheated
to 37C. Aliquots of the suspension were taken immedi-
ately and 60 and 120 min later. Placing the samples in an
ice bath stopped the repair incubation. Cells exposed to
10 lMH 2O2 served as a positive control, whereas lym-
phocytes with neither CAP nor H2O2 treatment were neg-
ative controls.
Data analysis
The values in this study were expressed as mean ± SEM
from three experiments, i.e. the data from three experi-
ments were pooled and the statistical parameters were
calculated. Data obtained from cell viability were expres-
sed as mean ± SD. Mann–Whitney U test was used to
determine differences between samples with the abnormal
distribution (Kolmogorov–Smirnov test). The differences
between samples with the normal distribution were evalu-
ated by applying the Student’s t test.
Results
Cell viability
Capecitabine at concentrations up to 500 lM did not affect
the viability of normal lymphocytes (Fig. 2, open symbols).
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of HTB-43 cancer cells (Fig. 2, closed symbols). At the
highest CAP concentration, 500 lM, almost all cancer cells
were dead, whereas the viability of normal lymphocytes
was about 88%.
DNA damage in vitro
Capecitabine did not introduce DNA breaks to isolated
DNA, as assessed by the plasmid relaxation assay, in which
the ratio of the amount of open circular form of plasmid
DNA to the total amount of DNA was calculated (Table 1,
Fig. 3). The plasmid used in our experiment was sensitive
to DNA-breaking agents, as checked by UV irradiation.
DNA damage in HTB-43 cells and lymphocytes
The dependence of DNA damage in human lymphocytes in
the alkaline version of the comet assay on CAP concen-
tration is displayed in Fig. 4. Single and double DNA
strand breaks as well as alkali labile sites can be detected in
this version of the technique. CAP evoked a dose-depen-
dent increase in the percentage of DNA in the percentage
of DNA in comet tail of HTB-43 cells and normal lym-
phocytes, but this increase was signiﬁcantly (P\0.05)
higher in the former than in the latter. The drug did not
affect the comet tail DNA in the neutral version of the
comet assay (data not shown), so we concluded that it had
no ability to induce this kind of DNA damage.
Fig. 2 Viability of head and neck squamous cell carcinoma HTB-43
cells (closed symbols) and normal human lymphocytes (open
symbols) exposed to CAP for 1 h at 37C and measured by ﬂow
cytometry with thiazole orange and PI. Displayed is the mean of three
experiments of 5 9 10
4 measurements each, error bars denote
standard deviation, *P\0.001. The contour diagrams above the plot
show results for one representative experiment out of three for each
CAP concentration
Table 1 Ratio of open circular DNA to the total amount of DNA (R)
of isolated pUC19 plasmid exposed to capecitabine
Capecitabine (lM) R
0 (negative control) 0.084
50 0.097
500 0.101
UV (positive control) 0.458*
The values for supercoiled DNA were multiplied by 1.66 to correct
for the decreased intercalating ability of ethidium bromide
* P\0.001 as compared with negative control
Fig. 3 DNA damage in isolated pUC19 plasmid incubated with CAP.
The picture shows three forms of the plasmid: linear (L), open circular
(OC) and supercoiled (SC) exposed to CAP at indicated concentra-
tions or 254 nm UV at dose rate of 0.12 J m
-2 s
-1 (positive control).
The samples were electrophoresed on a 1% agarose gel, stained with
ethidium bromide and visualized in UV light. Optical density of each
lane is plotted above it
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We analyzed the kinetics of DNA repair in HTB-43 cancer
cells and normal human lymphocytes by measuring the
extent of DNA damage in the cells exposed to CAP at 10 or
50 lM immediately after the exposure as well as 60 and
120 min thereafter (Fig. 5). In all cases, the comet tail
DNA of the control cells was constant. The cells exposed to
10 lM hydrogen peroxide (positive control) were able to
recover within 45 min (results not shown). Both kinds of
the cells recovered completely from DNA damage after
120 min.
Detection of DNA damage by DNA repair enzymes
Table 2 presents the mean percentage tail DNA of human
lymphocytes and HTB-43 cells exposed for 1 h at 37Ct o
CAP, lysed and post-treated with Endo III or Fpg, as
compared with the cells without treatment with any
enzyme. Both kinds of cells exposed to CAP and treated
with Endo III and Fpg showed greater percentage tail DNA
than those untreated with any enzyme. The difference
increased with the increasing concentration of CAP. We
observed also a signiﬁcant difference in the percentage tail
DNA of the cells post-treated and untreated with Endo III
in the absence of CAP, which arisen likely from the
endogenous oxidative damage to the DNA bases as well as
from the oxidative damage to DNA introduced during
isolation and subsequent processing of the cells.
Spin trapping
The mean percentage tail DNA of human lymphocytes and
HTB-43 cells exposed to CAP at 5 and 10 lM after pre-
treatment with 100 lM of the nitrone spin traps PBN and
POBN is presented in Fig. 6. Both traps signiﬁcantly
(P\0.001 for either CAP concentration) decreased the
extent of DNA damage evoked by CAP in both kinds of
cells.
Apoptosis
Capecitabine induced apoptosis in HTB-43 cells in a dose-
dependent manner (Fig. 7). At highest drug concentration,
500 lM, almost all cells underwent apoptosis and even at
50 lM the fraction of apoptotic cells exceeded 80%. CAP
did not induced apoptosis in normal lymphocytes.
Untreated lymphocytes were primarily Annexin V-FITC
and PI negative, indicating that they were viable and not
undergoing apoptosis, but this was not the case for the
HTB-43 cells, which signiﬁcant (about 30%) fraction went
apoptosis. After incubation with CAP there were basically
two populations of cancer cells: Annexin V-FITC positive
and PI negative (undergoing apoptosis) and Annexin
V-FITC and PI positive, indicating that they were in the
end stage of apoptosis or already dead.
Fig. 4 DNA damage in head and neck squamous cell carcinoma
HTB-43 cells (closed symbols) and normal human lymphocytes (open
symbols) exposed to CAP for 1 h at 37C. DNA damage was
measured as percentage in the tail DNA in comets of the alkaline
version of the comet assay. The mean value for one hundred cells
analyzed in each treatment in three independent experiments is
displayed, error bars represent SEM, *P\0.05 as compared with
lymphocytes at the same concentration
Fig. 5 Time-course of DNA repair in HNSCC HTB-43 cells (closed
symbols) and normal human lymphocytes (open symbols) exposed to
CAP for 1 h at 37Ca t1 0( diamonds)o r5 0lM( squares). DNA
damage was measured as percentage in the tail DNA in comets of the
alkaline version of the comet assay. The control HTB-43 cells (closed
circles) and lymphocytes (open circles) were not exposed to CAP.
After the exposure, the cells were washed and incubated in a cap-free
medium at 37C. The number of cells analyzed in each time-interval
was 100. The results are mean of three independent experiments.
Error bars denote SEM, for both HTB-43 and lymphocytes the extent
of DNA damage at 60 and 120 min was signiﬁcantly (P\0.001)
lower than at 0 min
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In order to determine whether CAP had an inﬂuence on the
progression of cell cycle, HTB-43 cells were exposed to
CAP at 50 and 500 lM and to 5 M nocodazole as a posi-
tive control (Fig. 8). CAP evoked a slow and mild increase
in the G0/G1 cell population accompanied by a faster
decrease in the S cell population. The G2/M population
was unaffected by CAP.
Discussion
The interaction between a chemical and a cell may depend
on the state of the cell, which, in turn, may be determined
by the state of an organism, from which this cell was
derived. This feature is very important in chemotherapy,
when the effect induced by a drug in target cancer cells
should be much more pronounced than in non-target nor-
mal cells. Therefore, it is important to identify mechanisms
determining differential response to a chemical in various
kinds of cells, including normal and cancer ones.
Capecitabine is an anticancer drug applied in metastatic
colorectal cancer. The drug is also approved for use in
metastatic breast cancer patients who are resistant to anthra-
cycline- and paclitaxel-based regimens or whom further
anthracycline treatment is not recommended. CAP can be
also used in combination with docetaxel, when anthracy-
cline-based chemotherapy is not efﬁcient. It is also reported
to bring beneﬁts in patients with prostate, pancreatic, renal
cell, and ovarian cancers. There are reports on potential
usefulness of CAP in head and neck cancer therapy. Three
aspects of anticancer drug should be taken into account,
when its usefulness in therapy of a particular cancer is
assessed. First, it should affectively kill cancer cells or
inhibit their proliferation. Second, it should have tolerable
side effects. Third, target cells should not acquire resis-
tance to it. In the present work we explored the ﬁrst two
issues of this dogma in the context of cyto- and genotox-
icity of CAP in cancer and normal cells. We showed that
CAP effectively killed HTB-43 head and neck cancer cells,
whereas it did not affect the viability of normal human
Table 2 DNA damage measured as percentage of DNA in tail comet in human lymphocytes and head and neck cancer HTB-43 cells exposed for
1ha t3 7 C to capecitabine with subsequent treatment with Endo III or Fpg at 1 lg/ml
Capecitabine (lM) %Tail DNA
Lymphocytes HTB-43
Endo III Fpg Endo III Fpg
0 3.2 ± 0.6 6.3 ± 0.8 4.1 ± 0.6 7.2 ± 0.9
5 7.4 ± 0.9*** 12.9 ± 1.4*** 10.8 ± 1.3*** 18.3 ± 2.3***
10 13.2 ± 1.4*** 19.4 ± 2.2*** 16.4 ± 1.7*** 22.1 ± 2.6***
50 16.9 ± 2.1*** 23.7 ± 2.5*** 24.6 ± 3.0*** 28.3 ± 3.1***
10 lMH 2O2 (positive control) 12.4 ± 1.4*** 16.3 ± 1.7*** 14.2 ± 1.6*** 19.7 ± 2.1***
The values given in the table are normalized to the values for cells treated with enzyme buffer only
Mean ± SE; *** P\0.001 as compared with appropriate controls not exposed to the drug
Fig. 6 DNA damage measured as mean comet tail DNA of normal
human lymphocytes and head and neck HTB-43 cancer cells
incubated for 15 h at 37C with CAP in the absence and in the
presence of POBN (black bars) or PBN (grey bars) at 100 M
compared with appropriate controls (empty bars). The number of cells
scored in each treatment was 100. The ﬁgure shows mean results from
three independent experiments. Error bars denote SEM; **P\0.01,
***P\0.001
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123lymphocytes. Moreover, CAP induced DNA damage in
HTB-43 cells, in contrary to normal lymphocytes. There-
fore, our results support the idea of keeping on investi-
gating on usefulness of CAP in head and neck therapy.
The main general mode of the anti proliferative action
of CAP is interfering with DNA synthesis in highly
proliferating cancer cells. We showed that the drug was
not able to interact with isolated DNA, which suggests
that such interaction, if any, requires chemical transfor-
mation of CAP or would be mediated by the presence of
other biological macromolecules, present in the cell. It
Fig. 7 Apoptosis of HNSCC HTB-43 cells (closed symbols) and
normal human lymphocytes (open symbols) exposed to CAP for 1 h at
37Ca t1 0( diamonds)o r5 0lM( squares). Apoptosis was assessed
by ﬂow cytometry with Annexin V-FITC/PI. Displayed is the mean of
three experiments of 5 9 10
4 measurements each, error bars denote
standard deviation. The contour diagrams above the plot show one
representative experiment out of three for each CAP concentration.
The lower left quadrant of each diagrams show the viable cells, which
exclude PI and are negative for Annexin V-FITC binding. The upper
right quadrants contain the non-viable, necrotic cells, positive for
Annexin V-FITC binding and for PI uptake. The lower left quadrants
represent the apoptotic cells, Annexin V-FITC positive and PI
negative, demonstrating cytoplasmic membrane integrity. The apop-
tosis was expressed as a ratio of the number of early and late apoptotic
cells to the number of cells with no measurable apoptosis
Fig. 8 Cell cycle analysis in HTB-43 cells exposed to CAP. Fraction
of cells in G0/G1 (white bars), S (light grey bars) and G2/M (dark
grey bars) stage of cell cycle after treatment with CAP was presented
along with histograms for each CAP concentration. Nocodazole at
5 lM was used as a positive control. Data are expressed as means of
at least three independent experiments, error bars denote SD,
*P\0.001 as compared with unexposed control
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123was partly conﬁrmed by the results of our next experi-
ment, in which we showed that CAP could induce dam-
age to DNA in head and neck cancer cells. This means
that a cellular environment is needed to activate CAP for
its DNA-damaging action. However, this cellular envi-
ronment can be attributed to cancer cells, since no DNA
damage was observed in normal cells. This is in line with
the idea of the prodrug and general mechanism of CAP
action, in which it requires metabolic activation by thy-
midine phosphorylase, present in tumor cells in much
higher amount than in normal cells.
In our research CAP effectively induced alkali labile
sites and/or DNA strand breaks in HTB-43 cells, as eval-
uated by the alkaline comet assay. However, we excluded
the induction of DNA double strand breaks from the
mechanism underlying genotoxicity of CAP, since the drug
did not caused any increase in the percentage of DNA in
tail of comet in the neutral version of the comet assay.
In general Fpg recognized more DNA damage than
Endo III, which may suggest that CAP preferentially
interacts with the DNA purines, but this conclusion is not
very important due to rather moderate differences between
the extent of DNA damage recognized by these two
enzymes and moderate speciﬁcity of both enzymes. But the
results obtained in this experiment directly show the
presence of oxidative damage to DNA after the action of
CAP.
The immediate question arises from the results obtained
on DNA-damaging potential of CAP in cancer cells:
whether it manifests a new mechanism of the action of
CAP in cancer cells or it is a consequence of its anti-
metabolite action. If we look at basic mechanisms of CAP
action, at least two of them may bring DNA damage as a
consequence. First, the inhibition of TS activity by CAP
causes a decrease in the amount of dTTT in replication
and repair, which may lead to decreased process of DNA
polymerases and eventually stop the synthesis of DNA.
Such incomplete synthesis would result in DNA structures
with single-stranded overhangs, recognized as damaged
DNA. Second, the effect of CAP may be intermediated by
incorporation of 5-FU in DNA. Such modiﬁed base is
recognized preferentially by MBD4, a DNA glycosylase
of base excision repair pathway [26]. This enzyme har-
bours an apurinic/apyrimidinic lyase activity in addition
to its DNA glycosylase activity. Therefore, MBD4 may
create DNA single strand breaks in sites of 5-FU incor-
poration. Normally, these breaks are sealed by DNA
polymerase a, but 5-FU may block TS activity and the
polymerase may encounter difﬁculties in putting dTTT in
the site previously occupied by 5-FU. This may result in
the persistence of DNA strand breaks, which can be
detected in the comet assay. Therefore, we suggest that
the DNA-damaging effect can be attributed to CAP, as a
consequence of its multi-pathway action. However, it
should be noted, that there are reports suggesting that
uracil incorporation into DNA did not predict genotoxi-
city of 5-FU followed from the inhibition of TS [27]. It
was reported, that uracil excision initiated by a uracil
glycosylase did not adequately explain the toxicity caused
by TS inhibition, which conﬁrms an earlier studies indi-
cating, that the expression of uracil DNA glycosylase did
not affect cellular sensitivity to TS inhibition [28]. These
reports did not indicate that the DNA-damaging effect of
CAP is not important for the toxicity of the drug, but they
rather suggest that the action of a uracil glycosylase itself
may not result in an immediate cellular toxicity. We share
this conclusion and add that a cross-talk between mech-
anisms of different pathways of CAP toxicity, including
DNA-damaging effect, may contribute to overall toxicity
of the drug in cancer cells.
We showed also that the drug induced apoptosis in
cancer cells. This effect can be rather related to the anti-
metabolic action of CAP, than to its ability to induce DNA
damage, since in the light of the lack of double strand
break breaks, the drug would have induced enormous
amount of single strand breaks and alkali labile sites and
this is rather unlikely, that it would do so only in cancer
cells. It was also suggested that genotoxic stress resulting
from the inhibition of TS might activate programmed cell
death pathways [29]. The observed changes in the cell
cycle progression are generally in line with results of other
results showing arrest of cells in early S phase after
treatment with TS inhibitors and resuming replication
progression during recovery from the treatment. Our
results suggest that this effect can be rather associated
with anti-metabolite than the DNA-damaging action of
CAP, since we did not observe changes in the G2/M
population.
Conclusions
Our results suggest that CAP may exert a pronounced cyto-
and genotoxic effect in head and neck cancer cells, while
affecting normal lymphocytes to a much lesser degree. This
may be useful in planning chemotherapeutic strategy in
head and neck cancer.
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